Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Bayer Builds China Diabetes Portfolio with SciLin Launch

publication date: Sep 7, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Bayer Schering Pharma has launched SciLin, its recombinant insulin product, in China. In June 2009, the company paid $43.5 million to Polish biotech Bioton for China rights to the drug over the next 15 years. At the time of the agreement, Bayer forecast that SciLin would generate between $1.5 billion and $2 billion of revenue in China during the life of the agreement. More details....

Stock Symbol: (XETRA: BAY)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners